ASSESSMENT OF THE COST-EFFECTIVENESS OF HOSHINO MUMPS VACCINE AMONG CHILDREN IN INDIA: EVIDENCE FROM A DECISION-TREE MODEL
Author(s)
Harsimran Kaur, PhD1, Yogesh Krishnarao Gurav, Sr., MD2, Biju Soman, MD3, Amol Deshmukh, M.Pharm1, Sunil Vaidya, MD2, Nitin Ambadekar, MD4, Harikumar S, MD5, Aarti Kinikar, MD6, Pravin Sawant, MPH1, Siddhant Lahase, BAMS1, Rehna C. Mohamed, MPH3.
1E solutions IT services Pvt. Ltd, HTA Resource Center, ICMR-National Institute of Translational Virology & AIDS Research, Pune, India, 2ICMR-National Institute of Translational Virology & AIDS Research, Pune, India, 3SCTIMST TRIVANDRUM, Trivandrum, India, 4State Health System Resource Centre, Pune, India, 5Directorate of Health Services, Kerala, India, 6BJ Medical College, Pune, India.
1E solutions IT services Pvt. Ltd, HTA Resource Center, ICMR-National Institute of Translational Virology & AIDS Research, Pune, India, 2ICMR-National Institute of Translational Virology & AIDS Research, Pune, India, 3SCTIMST TRIVANDRUM, Trivandrum, India, 4State Health System Resource Centre, Pune, India, 5Directorate of Health Services, Kerala, India, 6BJ Medical College, Pune, India.
OBJECTIVES: Measles mumps rubella (MMR) vaccination is a part of routine immunization schedules of over 122 countries. However, currently, only the MR vaccine is included in the universal immunization programme (UIP) of India. Recent focal outbreaks of mumps among children in Kerala state have highlighted the need for mumps vaccine inclusion in the UIP. The Hoshino strain of mumps vaccine has demonstrated appreciable immunogenicity and seroconversion rates in Asian populations, compared to other strains such as Jeryl Lynn and Leningrad-Zagreb. Thus, this study was conducted to determine the cost-effectiveness of MMR vaccine with the Hoshino strain of mumps vaccine.
METHODS: A decision-tree model was constructed to predict lifetime costs and outcomes from the Indian provider perspective. The intervention was Hoshino mumps strain in the MMR vaccine and the comparator was routine MR vaccination (children <5 years of age). A discounting rate of 3% was applied for costs, QALYs, and cases averted over a patient lifetime (70 years).
RESULTS: Incremental cost-effectiveness ratio (ICER) per mumps case averted and per quality adjusted life years (QALY) gained was found to be ₹1,209.62 and ₹1,759.06, respectively. One-way sensitivity analysis depicted that cost of vaccine, mumps infection probability, and symptomatic probability, exhibited the strongest influence on the upper and lower limits of the ICER. In case of probabilistic sensitivity analysis, all the iterations of the ICER per mumps case averted lay below the willingness-to-pay (WTP) threshold i.e., one GDP per capita of India at ₹2,30,000 (2025).
CONCLUSIONS: The possible introduction of Hoshino strain mumps vaccine in the current MR immunization schedule for children was found to be a cost-effective intervention. The incremental cost of introduction of the Hoshino mumps vaccine as MMR vaccine, in place of the current MR vaccines was found to be below the WTP threshold for the country.
METHODS: A decision-tree model was constructed to predict lifetime costs and outcomes from the Indian provider perspective. The intervention was Hoshino mumps strain in the MMR vaccine and the comparator was routine MR vaccination (children <5 years of age). A discounting rate of 3% was applied for costs, QALYs, and cases averted over a patient lifetime (70 years).
RESULTS: Incremental cost-effectiveness ratio (ICER) per mumps case averted and per quality adjusted life years (QALY) gained was found to be ₹1,209.62 and ₹1,759.06, respectively. One-way sensitivity analysis depicted that cost of vaccine, mumps infection probability, and symptomatic probability, exhibited the strongest influence on the upper and lower limits of the ICER. In case of probabilistic sensitivity analysis, all the iterations of the ICER per mumps case averted lay below the willingness-to-pay (WTP) threshold i.e., one GDP per capita of India at ₹2,30,000 (2025).
CONCLUSIONS: The possible introduction of Hoshino strain mumps vaccine in the current MR immunization schedule for children was found to be a cost-effective intervention. The incremental cost of introduction of the Hoshino mumps vaccine as MMR vaccine, in place of the current MR vaccines was found to be below the WTP threshold for the country.
Conference/Value in Health Info
2026-09, ISPOR Asia Pacific 2026, Bangkok, Thailand
Value in Health, Volume 55, Issue S1
Code
EE33
Topic
Economic Evaluation
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Pediatrics, STA: Vaccines